Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec combination anti-inflammatory and angiostatic treatment in hormone-refractory prostate cancer
2006-000218-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, pioglitazone, etoricoxib, dexamethasone and treosulfan in prostate cancer (PCa), sponsored by Novartis. Primary endpoint: Biochemical (PSA) response rate. Started Oct 2006; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-000218-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000218-19.